Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the assets of Promet Therapeutics, LLC in October of 2017 and assembled a proven regulatory science development team, management team, and Board of Directors. The Processa drug development team members have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. PCS-499 represents the first Processa drug that can potentially be used in several unmet medical need conditions.

Company profile
Ticker
PCSA
Exchange
Website
CEO
David Young
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Heatwurx, Inc.
SEC CIK
Corporate docs
Subsidiaries
Processa Therapeutics LLC ...
PCSA stock data
Press releases
Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
12 Aug 22
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
5 Aug 22
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
4 Aug 22
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
3 Aug 22
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
18 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.06M | 12.06M | 12.06M | 12.06M | 12.06M | 12.06M |
Cash burn (monthly) | 776.84K | 730.59K | 1.72M | 1.24M | 776.84K | 701.1K |
Cash used (since last report) | 1.28M | 1.2M | 2.84M | 2.04M | 1.28M | 1.16M |
Cash remaining | 10.78M | 10.86M | 9.22M | 10.02M | 10.78M | 10.91M |
Runway (months of cash) | 13.9 | 14.9 | 5.4 | 8.1 | 13.9 | 15.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Aug 22 | Sian Bigora | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,601 | 0 | 403,019 |
5 Aug 22 | Wendy Guy | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,601 | 0 | 189,528 |
5 Aug 22 | Patrick Lin | Common Stock | Payment of exercise | Dispose F | No | No | 3.17 | 2,656 | 8.42K | 438,335 |
5 Aug 22 | Patrick Lin | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,601 | 0 | 440,991 |
5 Aug 22 | Geraldine Pannu | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,169 | 0 | 11,269 |
5 Aug 22 | James H Stanker | Common Stock | Payment of exercise | Dispose F | No | No | 3.17 | 2,462 | 7.8K | 49,250 |
5 Aug 22 | James H Stanker | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,601 | 0 | 51,712 |
5 Aug 21 | Wendy Guy | Common Stock | Payment of exercise | Dispose F | No | No | 3.17 | 1,782 | 5.65K | 187,746 |
Institutional ownership, Q1 2022
84.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 52.2M |
Total shares | 13.4M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
David Young | 11.44M | $45.2M |
Yuhan (usa) | 750K | $2.96M |
Vanguard | 373.6K | $1.13M |
AIGH Capital Management | 303.7K | $915K |
Manchester Management | 142.43K | $819K |
Worth Venture Partners | 70.95K | $214K |
Geode Capital Management | 64.9K | $195K |
Verdence Capital Advisors | 59.88K | $180K |
Janney Montgomery Scott | 46.23K | $139K |
STT State Street | 41.49K | $125K |
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Continental, director, ensure, Equiniti, floor, hinder, modification, originally, put, rare, ratably, recommended, reelection, run, Trust, unamortized, unexpected, unknown
Removed:
activate, assay, attributable, biomarker, continuing, depreciation, determining, existing, measurement, medicine, precision, refining, specifically
Financial reports
Current reports
8-K
Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
12 Aug 22
8-K
Regulation FD Disclosure
4 Aug 22
8-K
Departure of Directors or Certain Officers
25 Jul 22
8-K
Departure of Directors or Certain Officers
14 Jul 22
8-K
Other Events
16 May 22
8-K
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
12 May 22
8-K
Entry into a Material Definitive Agreement
24 Mar 22
8-K
Regulation FD Disclosure
17 Mar 22
8-K
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
26 Jan 22
8-K
Material Modifications to Rights of Security Holders
6 Jan 22
Registration and prospectus
S-8
Registration of securities for employees
16 Aug 22
424B5
Prospectus supplement for primary offering
24 Mar 22
424B5
Prospectus supplement for primary offering
20 Aug 21
S-8
Registration of securities for employees
30 Jun 21
424B3
Prospectus supplement
12 Apr 21
S-3
Shelf registration
1 Apr 21
D
$10.24M in equity / options, sold $10.24M, 18 investors
19 Feb 21
424B4
Prospectus supplement with pricing info
5 Oct 20
S-1MEF
Registration of additional securities for an S-1
1 Oct 20
Proxies
DEFA14A
Additional proxy soliciting materials
31 May 22
DEFA14A
Additional proxy soliciting materials
20 Sep 21
PRE 14A
Preliminary proxy
1 Sep 21
DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEF 14C
Information statement
27 May 20
PRE 14C
Preliminary information
15 May 20
DEF 14C
Information statement
25 Nov 19
Other
EFFECT
Notice of effectiveness
12 Jul 21
CORRESP
Correspondence with SEC
5 Jul 21
UPLOAD
Letter from SEC
5 Jul 21
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
6 Apr 21
UPLOAD
Letter from SEC
4 Apr 21
EFFECT
Notice of effectiveness
2 Oct 20
CERT
Certification of approval for exchange listing
1 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
28 Sep 20
Ownership
4
Processa Pharmaceuticals / Justin W Yorke ownership change
8 Aug 22
4
Processa Pharmaceuticals / Geraldine Pannu ownership change
8 Aug 22
4
Processa Pharmaceuticals / James H Stanker ownership change
8 Aug 22
4
Processa Pharmaceuticals / David Young ownership change
8 Aug 22
4
Processa Pharmaceuticals / Sian Bigora ownership change
8 Aug 22
4
Processa Pharmaceuticals / Wendy Guy ownership change
8 Aug 22
4
Processa Pharmaceuticals / Patrick Lin ownership change
8 Aug 22
4
Processa Pharmaceuticals / VIRGIL THOMPSON ownership change
8 Aug 22
4
Processa Pharmaceuticals / James R Neal ownership change
21 Jul 22
3
Processa Pharmaceuticals / James R Neal ownership change
21 Jul 22
Reddit threads
Daily Discussion Thread - August 11th, 2022
11 Aug 22
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Daily Discussion Thread - March 30th, 2022
30 Mar 22
Daily Discussion Thread - March 29th, 2022
29 Mar 22
Daily Discussion Thread - March 28th, 2022
28 Mar 22
Daily Discussion Thread - March 24th, 2022
24 Mar 22
Daily Discussion Thread - March 23rd, 2022
23 Mar 22
Daily Discussion Thread - March 22nd, 2022
22 Mar 22